ZEGERID OTC (omeprazole, sodium bicarbonate) by Design Pharmaceuticals is proton pump inhibitors [moa]. First approved in 2009.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
ZEGERID OTC is an oral capsule combining omeprazole (a proton pump inhibitor) with sodium bicarbonate for over-the-counter treatment of heartburn and acid reflux. The sodium bicarbonate component enables rapid onset of action by neutralizing gastric acid, while omeprazole provides sustained acid suppression via proton pump inhibition. This combination addresses both immediate symptom relief and longer-term acid control.
As an OTC product approaching loss of exclusivity, the team is likely consolidating around market defense and cost management rather than expansion.
Proton Pump Inhibitors
Proton Pump Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ZEGERID OTC offers limited career growth due to its approaching loss of exclusivity and minimal linked job openings (0). This role is best suited for professionals seeking stable, maintenance-focused work in a mature OTC portfolio rather than innovation-driven advancement.
Worked on ZEGERID OTC at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.